Scientific deep-dive
How Many People to Treat to Help One
Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.
Trials almost always report benefit as a percentage reduction, which sounds impressive and tells you nothing about your own odds. The FLOW cardiovascular analysis did something rarer. It published the number needed to treat, which is how many people take the drug for three years so that one of them avoids the outcome.[1] The answers were 22, 13 and 17.
What number needed to treat means
A 26% reduction in risk is a ratio. It describes how much the odds shift, not how likely the event was to begin with. Cutting a 40% risk by a quarter is a very different proposition from cutting a 0.4% risk by a quarter, and the same percentage describes both.
Number needed to treat collapses that into one figure: treat this many people for this long, and one of them will avoid the event who otherwise would not have. It answers the question a patient is asking, and it is the statistic most papers leave out.
The trial and the subgroups
Everyone in FLOW had two diagnoses at once, type 2 diabetes and established kidney disease, and half of them drew weekly semaglutide at 1.0 mg. Its primary outcome combined serious kidney deterioration (a halving of filtration rate, filtration falling below 15, dialysis or transplantation) with kidney or cardiovascular death. This analysis split the trial by cardiovascular status at entry.
| Subgroup | With the condition | Without it | P interaction | NNT |
|---|---|---|---|---|
| Atherosclerotic CV disease | HR 0.80 (0.63–1.02) | HR 0.74 (0.62–0.89) | 0.62 | 22 |
| Heart failure | HR 0.67 (0.49–0.93) | HR 0.79 (0.67–0.93) | 0.40 | 13 |
| High total CV risk (PREVENT ≥20%) | HR 0.73 (0.58–0.91) | HR 0.73 (0.49–1.08) | 0.99 | 17 |
All-cause death moved in the same direction throughout, with hazard ratios between 0.71 and 0.82 across every subgroup and no sign of heterogeneity.
Why some intervals cross 1 and it does not matter here
Read down the hazard ratio columns and several intervals include 1: atherosclerotic disease at 0.63 to 1.02, all-cause death in the heart-failure group at 0.54 to 1.05. Taken alone, each of those says “not established.”
That is exactly what splitting a trial does. Halve the participants and you halve the events, which widens every interval regardless of whether the underlying effect changed. Subgroup intervals crossing 1 in a trial whose overall result was positive is the expected picture, not a warning sign.
That is the mirror image of a case we covered in the statistic that asks if groups differ, where an interaction P of .06 sat under a table that looked like a clean split. Same test, opposite reading, and the pair is more instructive than either.
Why you cannot carry these numbers elsewhere
So these figures say something precise and narrow: for people with diabetes and kidney disease, treating between 13 and 22 for three years prevents one serious kidney outcome. Applied to someone taking a GLP-1 for weight without kidney disease, they would be fabricated. We are not going to extrapolate them and nobody else should either. The same limit applies to the death results quoted as proof of longevity; see are GLP-1s longevity drugs?.
The dose matters too: semaglutide 1.0 mg, the type 2 diabetes strength, not the 2.4 mg used for weight management. For the kidney evidence more broadly, see GLP-1s and your kidneys.
Frequently Asked Questions
References
- 1.Tuttle KR, Bakris GL, Baeres FMM, et al. Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses Journal of the American College of Cardiology. 2026. PMID: 42233552.
- 2.Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force JAMA. 2022. PMID: 35997724.
Compare the sellers
Related research
Where the Evidence Is Strongest
Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.
7 min read
The Statistic That Asks If Groups Differ
A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.
7 min read
Tirzepatide vs Dulaglutide: A Real Head-to-Head
13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.
6 min read
GLP-1s After a Kidney Transplant
A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.
6 min read
Does Weight Loss Fake Kidney Numbers?
Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.
7 min read
Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1
SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.
12 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →